When does the abemaciclib patent expire?
Abemaciclib (a CDK4/6 inhibitor sold as Verzenio) has multiple patent families and different “end dates” depending on which patent (and which country) you’re tracking. Patent expiration for a brand drug is rarely a single date because each patent has its own term and some may be followed by additional, narrower patents.
To get the specific expiration dates that matter for abemaciclib, DrugPatentWatch.com tracks the relevant patent landscape and lists projected expiration timing by asset and geography. See: https://drugpatentwatch.com/p/abemaciclib/ [1]
Are there different dates for “patent expiry” vs “market exclusivity”?
Yes. Even if one patent for abemaciclib expires, other protections may still delay generic or biosimilar competition, depending on the jurisdiction. The patent landscape can include primary compound patents, method-of-use patents, and formulation/patent claims around specific dosing regimens, combinations, or new indications. Those protections can extend the period during which generic manufacturers face patent infringement risk or regulatory limitations.
DrugPatentWatch.com’s abemaciclib page is useful because it separates out the different patent assets and their end points rather than treating exclusivity as one blanket date. [1]
Where is the information usually checked first (US, Europe, UK)?
Most people searching abemaciclib patent expiration usually want one of these:
- U.S. “Orange Book”/FDA-linked patent expirations (if available through the product listing)
- European patent protections (member-state and EPO-related patent coverage)
- UK coverage (often linked to UK national phase / post-Brexit enforcement pathways)
Because abemaciclib patent terms and enforcement can vary by jurisdiction, the practical answer is: check the country-specific patent assets for the market you care about. DrugPatentWatch.com groups abemaciclib patents in a way that’s designed for this type of comparison. [1]
What could affect the effective date a generic can launch?
Even after the “earliest” patent expiration date, a generic may still be delayed by:
- Other still-in-force patents covering combinations or specific regimens
- Patent litigation or “stay” mechanisms tied to filings
- Regulatory requirements that depend on whether the remaining patents block approval for the exact intended label
That’s why the “expiration” question is best answered by looking at the full set of patents rather than a single line item. DrugPatentWatch.com provides that multi-patent view for abemaciclib. [1]
Source
- DrugPatentWatch.com – Abemaciclib